Clin Pediatr Hematol Oncol.  2011 Apr;18(1):58-61.

A Case of High Dose Oseltamivir Treatment in an Influenza A (H1N1) Infected Patient with Severe Graft Versus Host Disease

• Kim AR
• Kim ES
• Pai KS
• Park JE

Abstract

Influenza A (H1N1) infection has been noted to be common in the young and high-risk groups for influenza infection, including transplant candidates and recipients. However, the optimal dosage and duration of oseltamivir for severely immunocompromised patients have not been defined. We report the case of a patient with relapsed neuroblastoma who was infected with influenza A (H1N1) and suffered from skin and lung graft versus host disease after he had received allogeneic hematopoietic stem cell transplantation from a matched sibling donor. During the immunosuppressant therapy, he was diagnosed with influenza A (H1N1) infection by real time polymerase chain reaction (RT-PCR). He recovered after oseltamivir treatment with a dosage of 90 mg twice a day for two weeks, which was two times of the standard dose until influenza A (H1N1) RT-PCR was proven to be negative.

Keyword

H1N1 virus; Graft vs host disease; Transplantation; Homologous

MeSH Terms

Graft vs Host Disease
Hematopoietic Stem Cell Transplantation
Humans
Immunocompromised Host
Influenza A Virus, H1N1 Subtype
Influenza, Human
Lung
Neuroblastoma
Oseltamivir
Real-Time Polymerase Chain Reaction
Siblings
Skin
Tissue Donors
Transplants
Oseltamivir